Key result
Finerenone cuts composite CV events ~14% vs placebo across SBP variability quartiles.
Why the study?
High systolic blood pressure variability is associated with mineralocorticoid receptor activation and adverse cardiovascular and kidney outcomes, motivating an evaluation of outcome associations and finerenone treatment effects across blood pressure variability strata in patients with CKD and T2D.
Does finerenone reduce composite cardiovascular and kidney outcomes across different levels of systolic blood pressure variability in patients with chronic kidney disease and type 2 diabetes?
RCT
Placebo-controlled
1:1
Does finerenone reduce composite cardiovascular and kidney outcomes across different levels of systolic blood pressure variability in patients with chronic kidney disease and type 2 diabetes?
Finerenone consistently reduces cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes regardless of visit-to-visit systolic blood pressure variability.
Answers are grounded in this paper and cite their sources.
Finerenone reduces composite CV events in CKD and T2D; confirms overall benefit with consistent effects across SBP variability levels.
Introduction High blood pressure (BP) variability is associated with increased aldosterone and mineralocorticoid receptor (MR) activation, and high visit-to-visit systolic BP (SBP) variability is associated with increased risks of cardiovascular (CV) events and chronic kidney disease (CKD). In FIDELITY, a prespecified pooled analysis of the phase III FIDELIO-DKD and FIGARO-DKD trials, the non-steroidal MR antagonist finerenone significantly reduced the risk of CV and adverse kidney outcomes vs placebo in patients with CKD and type 2 diabetes (T2D). Purpose This FIDELITY post hoc subanalysis evaluated the association between SBP variability and CV and kidney outcomes. Additionally, the finerenone treatment effect across levels of SBP variability was assessed. Methods Patients in FIDELITY were on optimised renin–angiotensin system inhibition and randomised 1:1 to finerenone or placebo. Outcomes included composite CV (CV death, non-fatal myocardial infarction, non-fatal stroke, or hospitalisation for heart failure) and composite kidney (kidney failure, sustained ≥57% decrease in estimated glomerular filtration rate from baseline over at least 4 weeks, or kidney-related death). SBP recorded at pre-screening, screening, baseline (pre-treatment) and up to 1 year from baseline after titration at month 1 (post-treatment) were used. The effect of finerenone vs placebo on outcomes was assessed across strata of pre- and post-treatment SBP variability (quartile 1 as the lowest and quartile 4 as the highest). SBP variability was estimated using standard deviation. A stratified Cox proportional hazards model was used to assess the associations of SBP variability with clinical outcomes and the finerenone treatment effects across SBP variability quartiles. Results Higher pre-treatment SBP variability was associated with increased probabilities of CV and kidney events over 3.5 years in both treatment groups (Fig). Over a median follow-up period of 3 years (interquartile range 2.3–3.8 years), finerenone reduced composite CV (hazard ratio [HR] 0.86; 95% confidence interval [CI] 0.78–0.95) and kidney outcomes (HR 0.76; 95% CI 0.66–0.88) vs placebo across SBP variability quartiles (pinteraction≥0.1741 and pinteraction≥0.5267, respectively). A trend was observed for a greater finerenone impact on CV outcomes at the highest levels of SBP variability (HR 0.72; 95% CI 0.60–0.87). Overall, finerenone and placebo showed comparable safety profiles. Conclusions In FIDELITY, higher SBP variability was associated with increased risk of adverse CV and kidney outcomes. Finerenone lowered the risk of CV and kidney outcomes vs placebo in patients with CKD and T2D irrespective of SBP variability. The treatment effect of finerenone is not modified by SBP variability and may confer benefit compared with placebo in those with high SBP variability.
No takes yet. Share an insight, caveat, or question.
Rajagopalan et al. (2026) conducted an RCT in Chronic kidney disease and type 2 diabetes. Finerenone vs. Placebo was evaluated on Composite cardiovascular outcome (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalisation for heart failure) (HR 0.86, 95% CI 0.78-0.95). Finerenone reduced composite CV and kidney outcomes vs placebo across SBP variability quartiles.
Synapse has enriched 10 related papers. Consider them for comparative context: